vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Essent Group Ltd. (ESNT). Click either name above to swap in a different company.
Essent Group Ltd. is the larger business by last-quarter revenue ($312.4M vs $183.1M, roughly 1.7× Amphastar Pharmaceuticals, Inc.). Essent Group Ltd. runs the higher net margin — 49.6% vs 13.3%, a 36.3% gap on every dollar of revenue. On growth, Essent Group Ltd. posted the faster year-over-year revenue change (-0.8% vs -1.8%). Essent Group Ltd. produced more free cash flow last quarter ($848.7M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 2.3%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.
AMPH vs ESNT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $312.4M |
| Net Profit | $24.4M | $155.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 59.1% |
| Net Margin | 13.3% | 49.6% |
| Revenue YoY | -1.8% | -0.8% |
| Net Profit YoY | -35.7% | -7.7% |
| EPS (diluted) | $0.51 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $312.4M | ||
| Q3 25 | $191.8M | $311.8M | ||
| Q2 25 | $174.4M | $319.1M | ||
| Q1 25 | $170.5M | $317.6M | ||
| Q4 24 | $186.5M | $315.0M | ||
| Q3 24 | $191.2M | $316.6M | ||
| Q2 24 | $182.4M | $312.9M | ||
| Q1 24 | $171.8M | $298.4M |
| Q4 25 | $24.4M | $155.0M | ||
| Q3 25 | $17.4M | $164.2M | ||
| Q2 25 | $31.0M | $195.3M | ||
| Q1 25 | $25.3M | $175.4M | ||
| Q4 24 | $38.0M | $167.9M | ||
| Q3 24 | $40.4M | $176.2M | ||
| Q2 24 | $37.9M | $203.6M | ||
| Q1 24 | $43.2M | $181.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 59.1% | ||
| Q3 25 | 13.2% | 63.9% | ||
| Q2 25 | 24.2% | 72.4% | ||
| Q1 25 | 21.9% | 65.2% | ||
| Q4 24 | 24.2% | 61.9% | ||
| Q3 24 | 29.8% | 65.6% | ||
| Q2 24 | 30.3% | 76.4% | ||
| Q1 24 | 27.9% | 71.6% |
| Q4 25 | 13.3% | 49.6% | ||
| Q3 25 | 9.0% | 52.7% | ||
| Q2 25 | 17.8% | 61.2% | ||
| Q1 25 | 14.8% | 55.2% | ||
| Q4 24 | 20.4% | 53.3% | ||
| Q3 24 | 21.1% | 55.6% | ||
| Q2 24 | 20.8% | 65.1% | ||
| Q1 24 | 25.1% | 60.9% |
| Q4 25 | $0.51 | $1.61 | ||
| Q3 25 | $0.37 | $1.67 | ||
| Q2 25 | $0.64 | $1.93 | ||
| Q1 25 | $0.51 | $1.69 | ||
| Q4 24 | $0.74 | $1.59 | ||
| Q3 24 | $0.78 | $1.65 | ||
| Q2 24 | $0.73 | $1.91 | ||
| Q1 24 | $0.81 | $1.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $5.8B |
| Total Assets | $1.6B | $7.4B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $5.8B | ||
| Q3 25 | $776.7M | $5.7B | ||
| Q2 25 | $757.5M | $5.7B | ||
| Q1 25 | $751.3M | $5.7B | ||
| Q4 24 | $732.3M | $5.6B | ||
| Q3 24 | $727.7M | $5.6B | ||
| Q2 24 | $713.3M | $5.4B | ||
| Q1 24 | $672.4M | $5.2B |
| Q4 25 | $1.6B | $7.4B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.6B | $7.2B | ||
| Q1 25 | $1.6B | $7.2B | ||
| Q4 24 | $1.6B | $7.1B | ||
| Q3 24 | $1.5B | $7.1B | ||
| Q2 24 | $1.5B | $6.7B | ||
| Q1 24 | $1.6B | $6.6B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $856.1M |
| Free Cash FlowOCF − Capex | $24.6M | $848.7M |
| FCF MarginFCF / Revenue | 13.4% | 271.7% |
| Capex IntensityCapex / Revenue | 4.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.35× | 5.52× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $856.1M | ||
| Q3 25 | $52.6M | $215.9M | ||
| Q2 25 | $35.6M | $189.5M | ||
| Q1 25 | $35.1M | $221.6M | ||
| Q4 24 | $29.0M | $861.5M | ||
| Q3 24 | $60.0M | $229.2M | ||
| Q2 24 | $69.1M | $188.7M | ||
| Q1 24 | $55.3M | $216.9M |
| Q4 25 | $24.6M | $848.7M | ||
| Q3 25 | $47.2M | $210.6M | ||
| Q2 25 | $25.0M | $188.8M | ||
| Q1 25 | $24.4M | $221.3M | ||
| Q4 24 | $16.6M | $854.8M | ||
| Q3 24 | $46.2M | $228.7M | ||
| Q2 24 | $63.1M | $187.6M | ||
| Q1 24 | $46.5M | $212.5M |
| Q4 25 | 13.4% | 271.7% | ||
| Q3 25 | 24.6% | 67.5% | ||
| Q2 25 | 14.3% | 59.2% | ||
| Q1 25 | 14.3% | 69.7% | ||
| Q4 24 | 8.9% | 271.3% | ||
| Q3 24 | 24.1% | 72.2% | ||
| Q2 24 | 34.6% | 60.0% | ||
| Q1 24 | 27.1% | 71.2% |
| Q4 25 | 4.5% | 2.4% | ||
| Q3 25 | 2.8% | 1.7% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.1% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 3.3% | 0.3% | ||
| Q1 24 | 5.1% | 1.5% |
| Q4 25 | 1.35× | 5.52× | ||
| Q3 25 | 3.03× | 1.31× | ||
| Q2 25 | 1.15× | 0.97× | ||
| Q1 25 | 1.39× | 1.26× | ||
| Q4 24 | 0.76× | 5.13× | ||
| Q3 24 | 1.48× | 1.30× | ||
| Q2 24 | 1.82× | 0.93× | ||
| Q1 24 | 1.28× | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
